Fujifilm Increases Production Capacity and Establishes New Process Development Facilities with JPY14 Billion ($130M USD) Investment to Support Growing Market Demand
18.4.2017 04:30 | Business Wire
FUJIFILM Corporation (President: Kenji Sukeno) will increase production capacity by investing about JPY14 billion ($130m) in the USA and UK in order to expand the business of its BioCDMO Division.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170417005993/en/
FDBT College Station, Texas cGMP Monoclonal Antibody production facility (Photo: Business Wire)
In the USA, at FUJIFILM Diosynth Biotechnologies Texas, LLC (FDBT), a JPY10 billion ($93m) cGMP production facility has been completed. This facility was built in part with funding from BARDA (Biomedical Advanced Research and Development Authority), an office of the U.S. Department of Health and Human Services, and Fujifilm plans to invest an additional JPY3 billion ($28m) to outfit the facility with mammalian cell culture bioreactors. This facility will start operation at the beginning of 2018. FUJIFILM Diosynth Biotechnologies Texas, LLC (FDBT) was acquired by Fujifilm through FUJIFILM Diosynth Biotechnologies U.S.A., Inc. (FDBU) in 2014. In March of this year, FDBT became a wholly owned subsidiary of FDBU exercising the option early included in the initial deal to take 100% ownership. In addition, a JPY1 billion ($9m) investment will be made to expand the Process Development capabilities at FUJIFILM Diosynth Biotechnologies UK Limited near to its Billingham, UK site. This facility is scheduled to be operational in summer of 2017.
The FDBT facility will be the manufacturing center of excellence for the company’s Saturn Monoclonal Antibody Platform with an initial cell culture capacity of 6,000L (3X 2000L bioreactors). The design of the facility allows for future expansion that can accommodate up to 24,000L of upstream capacity to meet much needed customers’ clinical and commercial demands. In the United Kingdom, the investments include the establishment of a dedicated Mammalian Cell Culture Center of Excellence. These laboratories span over 10,000 sq. ft. and are designed to incorporate the latest high-throughput technologies, including fully automated bioreactors and chromatography systems, to enable for rapid and efficient monoclonal antibody manufacturing process readiness. These assets will enable Fujifilm to provide 'best in class' facilities, technology and operational know how to the industry. They are also a key in our continuing commitment to develop future Medical Counter Measures and Pandemic Flu response candidates for our long term Partners the CIADM (Center for Innovation in Advanced Development and Manufacturing), BARDA and other third party customers.
“FUJIFILM Diosynth Biotechnologies is committed to its vision of being Leaders in the Bio CDMO space,” said Steve Bagshaw, Chief Executive Officer, FUJIFILM Diosynth Biotechnologies, “Our commitment is to transform the CDMO business through innovation and with our great people – providing long term support to our partners fulfilling our core purpose as ‘Partners for Life - Advancing tomorrow’s medicines’.”
Biopharmaceutical production requires the use of advanced manufacturing technologies and facilities for culturing, separation and purification. The number of companies outsourcing process development and manufacturing activities of biopharmaceuticals to CDMOs is increasing. The contract development and manufacturing market is projected to achieve growth of 8% per annum* accordingly.
Fujifilm will continue to grow and expand its existing capabilities in addition to engaging in external collaborations to increase capacity, and it will further develop high efficiency and high productivity technology by combining group technologies, to continue to grow further the business. It is targeting sales of JPY100 billion in its BioCDMO business by 2023.
* According to Fujifilm data
FUJIFILM Diosynth Biotechnologies is an industry-leading Biologics Contract Development and Manufacturing Organization (CDMO) with locations in Billingham, UK, RTP, North Carolina and College Station, Texas. FUJIFILM Diosynth has over twenty five years of experience in the development and manufacturing of recombinant proteins, vaccines, monoclonal antibodies, among other large molecules, viral products and medical countermeasures expressed in a wide array of microbial, mammalian, and host/virus systems. The company offers a comprehensive list of services from cell line development using its proprietary pAVEway™ microbial and Apollo™ cell line systems to process development, analytical development, clinical and FDA-approved commercial manufacturing. FUJIFILM Diosynth Biotechnologies is a partnership between FUJIFILM Corporation and Mitsubishi Corporation. For more information, go to: www.fujifilmdiosynth.com.
FUJIFILM Holdings Corporation, Tokyo, Japan (TOKYO: 4901) brings continuous innovation and leading-edge products to a broad spectrum of industries, including: healthcare, with medical systems, pharmaceuticals and cosmetics; graphic systems; highly functional materials, such as flat panel display materials; optical devices, such as broadcast and cinema lenses; digital imaging; and document products. These are based on a vast portfolio of chemical, mechanical, optical, electronic, software and production technologies. Fujifilm is committed to environmental stewardship and good corporate citizenship. For more information, please visit: www.fujifilmholdings.com.
FUJIFILM Corporation Corporate Communications Division
TEL +81 3-6271-2000
FUJIFILM Corporation Bio CDMO Division
TEL +81 3-6271-2171
Om Business Wire
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Xylem joins water industry leaders and policy influencers at World Water Week 2017 to advance water and wastewater management practices24.8.2017 09:00 | Pressemelding
At World Water Week 2017 in Stockholm, Xylem (NYSE:XYL), a leading global water technology company, will lead and participate in forums focused on accelerating the smarter management of water and wastewater. Taking place from August 27- September 1, World Water Week will center on the theme of “Water and Waste: Reduce and Reuse” and be attended by more than 3,000 professionals from some 300 businesses, agencies and non-governmental organizations. On Sunday, August 27, Xylem is co-convening a forum entitled “Data Drought: An Assessment of Global Hydrological Monitoring Systems” along with Duke University, the Aspen Institute and the University of Oxford. This multi-stakeholder discussion will assess the severe decline in critical global water monitoring infrastructure, explore the challenges and solutions to up-scaling this infrastructure as well as the implications of non-action, and d
Announcement from SII Semiconductor Corporation: Change of Company Name24.8.2017 06:00 | Pressemelding
SII Semiconductor Corporation (President: Nobumasa Ishiai, Head Office: Chiba-shi, Chiba; hereinafter “SII Semiconductor”), a subsidiary of Seiko Instruments Inc. (President: Hitoshi Murakami, Head Office: Chiba-shi, Chiba; hereinafter “SII”), that manufactures and sells semiconductors today announced that the company will change its company name to ABLIC Inc. in January 5, 2018. SII Semiconductor was established in September 2015. Through a joint investment by Development Bank of Japan Inc. (President & CEO: Masanori Yanagi, Head Office: Chiyoda-ku, Tokyo; hereinafter “DBJ”) in January 2016, SII Semiconductor has deployed and expanded its business by succeeding the SII’s semiconductor business. Currently the equity of SII Semiconductor is split to 60% for SII and 40% for DBJ, but SII will transfer its 30% of the equity to DBJ and DBJ will acquire 70% after January 2018. Taking adv
Ford Names New Chairman and CEO for Ford China; New Vice President of Powertrain Engineering23.8.2017 22:00 | Pressemelding
Ford Motor Company today announced a new chairman and CEO of Ford China and head of Powertrain Engineering as it continues to strengthen its global leadership team. Jason Luo is named chairman and CEO Ford China. In his new role, Luo will lead all of the company’s operations in Greater China including its import business, Lincoln, its passenger car joint venture Changan Ford, commercial vehicle investment in Jiangling Motors Corporation, and our operations in Taiwan. Luo, 51, joins Ford from Key Safety Systems, the fastest growing company in the automotive safety market, where he was global president and CEO for the past 10 years. While at Key Safety Systems, he led the business transformation and global expansion of the company and achieved significant revenue growth in China. Luo will be based in Shanghai, reporting to Peter Fleet, Ford group vice preside
Tech21 Announces New Collection Designed to Protect the Samsung Galaxy Note8 Drop After Drop.23.8.2017 17:30 | Pressemelding
Tech21, the leader in impact protection for mobile devices, today announced a new collection of innovative cases and screen shields for the Samsung Galaxy Note8 made of unique, patented impact protection materials that guarantee the most effective drop protection on the market. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170823005888/en/ Evo Tactical for Samsung Galaxy Note8 (Photo: Business Wire) Tech21 products are designed to protect, drop after drop. The company does this by using scientifically proven impact materials, innovative design and a rigorous testing methodology developed in partnership with the National Physical Laboratory. Tech21 cases are drop tested 20 times to ensure durability and long lasting protection able to withstand the multiple drops that occur in the everyday
2018 AQR Insight Award Call for Papers23.8.2017 15:45 | Pressemelding
AQR Capital Management, LLC (“AQR”) today began accepting submissions for the seventh annual AQR Insight Award. The AQR Insight Award recognizes and rewards exceptional academic papers that have practical applications and offer original, intelligent approaches to issues in the investment world. Up to three papers share a $100,000 annual prize. Winners are chosen by the AQR Insight Award Committee, a panel of senior members of the firm, many of whom are leading academic finance experts from top universities. AQR will accept papers on any investment-related topic as long as they deliver clear, significant insights. Papers must not be published before October 1, 2017. The deadline for entries is November 1, 2017. The Committee will then narrow the finalists to five papers, and the authors of those papers will be invited to present their research to
ANA Announces New Online Content "IS JAPAN COOL? DOU"23.8.2017 15:00 | Pressemelding
Today, All Nippon Airways Co., Ltd. (ANA), Japan’s largest and only 5-Star airline, is proud to announce the launch of its new online content “IS JAPAN COOL? DOU,” which illustrates traditional Japanese culture through the use of cutting-edge technology. This content can be seen on “IS JAPAN COOL?,” a website that promotes tourist destinations and popular Japanese cultures to the world. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170823005024/en/ "IS JAPAN COOL? DOU" TOP (Graphic: Business Wire) While Japan is widely known for its unique pop culture, “IS JAPAN COOL?,” which launched in 2012, has put much of its focus on promoting Japan’s modern culture. As the number of tourists visiting Japan exceeded 24 million people as of 2016, the project aims to provide a deeper understa
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom